NewCardio to Present Study of my3KG Performance at the Society for Academic Emergency Medicine Annual Meeting.
Mar 15, 2011 (Close-Up Media via COMTEX) -- NewCardio, Inc., a cardiovascular
diagnostic solutions developer, announced that the results of a my3KG
performance study will be made at the Society for Academic Emergency Medicine
(SAEM) Annual Meeting, to be held in Boston, June 1-5.
According to a release, the study, entitled "A New Computer Algorithm Performs
Better than Cardiologists in the Diagnosis of Acute Myocardial Infarction," will
be presented at the SAEM meeting by Dr. Stephen W. Smith, Associate Professor of
Emergency Medicine, University of Minnesota and Hennepin County Medical Center
(HCMC), Minneapolis MN. Co-investigators in this study included Drs. Victor Romo
and James Miner, Emergency Medicine, HCMC; and Drs. Dajuanna Lakireddy, Subba
Vanga, and Sudha Bommana, Kansas University Cardiovascular Research Institute,
Kansas City, KS.
The SAEM presentation will address a key diagnostic problem in Emergency
Department (ED) patients the low diagnostic sensitivity of the standard 12-lead
ECG in early diagnosis of acute myocardial infarction (MI).
Dr. Smith commented, "The standard 12-lead ECG plays a critical role in MI
diagnosis, but its low sensitivity even with expert physician interpretation -
leads to diagnostic delays and errors. To the extent that my3KG can improve
diagnostic sensitivity for acute MI, it is an important result that may lead to
faster and more accurate MI diagnosis in the ED."
Dr. Ihor Gussak, NewCardio's Chief Medical Officer, commented, "We were
delighted that Dr. Smith collaborated with us in this study. He is an
internationally known and well-respected emergency medicine specialist with
particular expertise in clinical electrocardiology and diagnosis of acute
coronary syndromes. He is highly influential among ED physicians, who represent
a key potential constituency for my3KG. We look forward to the SAEM
presentation, and to completing additional studies with Dr. Smith and his
colleagues, as we further develop my3KG."
NewCardio noted that its 3-D ECG platform technology improves the accuracy and
significantly increases the diagnostic value of the standard 12L ECG. NewCardio
is developing the my3KG solution for urgent diagnosis of serious cardiac
conditions, including AMI. In clinical studies to date, the my3KG has shown
substantially improved diagnostic accuracy relative to the standard 12L ECG,
particularly in the most diagnostically challenging patients (such as those with
diabetes and electrical conduction abnormalities). Accordingly, the Company
believes that its my3KG solution will substantially improve diagnostic timing
and accuracy in life-threatening cardiac conditions, and will thereby improve
clinical outcomes for a broad range of cardiac patients. The Company plans to
file a 510(k) application in late 2011 or early 2012 for FDA approval to market
my3KG in the U.S.
The SAEM is dedicated to the improvement of care of the acutely ill and injured
patient by improving research and education. To achieve this mission, SAEM
influences health policy through forums, publications, inter-organizational
collaboration, policy development, and consultation services for physicians,
teachers, researchers, and students.
